0001437749-19-022222.txt : 20191108 0001437749-19-022222.hdr.sgml : 20191108 20191108200046 ACCESSION NUMBER: 0001437749-19-022222 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191106 FILED AS OF DATE: 20191108 DATE AS OF CHANGE: 20191108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DE GREEF RODERICK CENTRAL INDEX KEY: 0001241181 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 191205400 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2019-11-06 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001241181 DE GREEF RODERICK C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 Chief Financial Officer Common Stock 2019-11-06 4 M 0 10000 1.64 A 35859 D Common Stock 2019-11-06 4 S 0 10000 17.81 D 25859 D Common Stock 2019-11-07 4 M 0 10000 1.76 A 35859 D Common Stock 2019-11-07 4 S 0 10000 17.08 D 25859 D Common Stock 2019-11-08 4 M 0 10000 1.76 A 35859 D Common Stock 2019-11-08 4 S 0 10000 16.44 D 25859 D Employee Stock Option 1.64 2019-11-06 4 M 0 10000 0 D 2019-03-01 2021-12-20 Common Stock 10000 6919 D Employee Stock Option 1.76 2019-11-07 4 M 0 10000 0 D 2026-03-04 Common Stock 10000 90000 D Employee Stock Option 1.76 2019-11-08 4 M 0 10000 0 D 2026-03-04 Common Stock 10000 80000 D Employee Stock Option 1.8099 2026-05-03 Common Stock 104000 104000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.16 to $18.65 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 to $17.61 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.60 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. /s/ Roderick de Greef 2019-11-08